Dear pharma & life sciences colleagues
Brexit is coming closer every day with many aspects still unclear which makes it hard for you to prepare for it.
We’re excited to take a closer look at the current status quo and the impact of Brexit on indirect taxes, movement of goods and trade for Pharma, Life Sciences and MedTech Companies.
Continue reading The impact of Brexit on Pharma, Life Science and MedTech companies – A PwC Pharma & Life Sciences Webinar
Discover PwC’s four cutting edge digital tax & regulatory solutions and how they can add value to your business, help you complying with new laws, stay up to date with upcoming changes in legislation and regulatory.
Continue reading Pharma & Life Sciences: 4 cutting edge digital tax & regulatory solutions
Medical devices suppliers conducting agreements for allowing hospitals to use free of charge their equipment might face both VAT and corporate tax adverse implications.
Continue reading Cutting edge tax implications for medical devices suppliers in Europe
gilt als Kernwert des Wirtschaftsstandorts Schweiz – und der MedTech-Branche.
Das Volks-Ja zur Steuerreform hat der innovativen Tätigkeit von Unternehmen wie
Ihrem eine neue Bedeutung verliehen. Auch andere nationale und internationale
Neuerungen der indirekten Steuern und Zölle sowie neue regulatorische
Rahmenbedingungen wirken sich 2020 auf die aktuelle und zukünftige Situation Ihres
Wie daraus ein echter
Mehrwert generiert werden kann, möchten wir gerne an unserem speziell der
MedTech Branche gewidmeten Event mit Ihnen diskutieren.
Continue reading Event: “Tax Engineering” für MedTech – 19. März 2020, PwC Luzern
1. The background in a nutshell
- Until 25th May 2020
all Medtech products that are admitted in Switzerland for the sale can be
distributed also in the EU.
- However, currently a
new treaty is negotiated by Switzerland and the EU Joint Committee in that
- In case the treaty is
not going to be concluded between Switzerland and the EU, all Medtech
companies based in Switzerland are considered as not being anymore part of the
EU. Indeed this treaty hangs by a
the latest developments of the Swiss-EU negotiations concerning the
Institutional Agreement and the Mutual Recognition Agreement (MRA),
Swiss Medtech companies should be preparing for the case in which MRA would
no longer apply to the medical devices after 26th May 2020.
Continue reading Swiss Medtech companies – action required for the sale of products in the EU as per May 2020 – Is your business ready for the upcoming changes?